Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Katie McFaul, Neill Liptrott, Alison Cox, Phillip Martin, Deirdre Egan, Andrew Owen, Sarah Kelly, Zeenat Karolia, Kate Shaw, Mark Bower & Marta Boffito. (2016) Cytotoxic chemotherapy and the evolution of cellular and viral resistance to antiretroviral therapy in HIV- infected individuals with lymphoma. HIV Clinical Trials 17:5, pages 197-203.
Read now
Read now
Alessia Uglietti, Domenico Zanaboni, Mariarosaria Gnarini & Renato Maserati. (2012) Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation. Expert Opinion on Drug Metabolism & Toxicology 8:10, pages 1305-1314.
Read now
Read now
Articles from other publishers (17)
Thabani Sibiya, Terisha Ghazi & Anil Chuturgoon. (2022) The Potential of Spirulina platensis to Ameliorate the Adverse Effects of Highly Active Antiretroviral Therapy (HAART). Nutrients 14:15, pages 3076.
Crossref
Crossref
Desire Takou, Joseph Fokam, Georges Teto, Maria-Mercedes Santoro, Francesca Ceccherini-Silberstein, Aubin Joseph Nanfack, Samuel Martin Sosso, Béatrice Dambaya, Romina Salpini, Serge Clotaire Billong, Caterina Gori, Charles Ntungwen Fokunang, Giulia Cappelli, Vittorio Colizzi, Carlo-Federico Perno & Alexis Ndjolo. (2019) HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon. BMC Infectious Diseases 19:1.
Crossref
Crossref
Romina Quercia, Carlo-Federico Perno, Justin Koteff, Katy Moore, Cynthia McCoig, Marty St. Clair & Daniel Kuritzkes. (2018) Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes 78:2, pages 125-135.
Crossref
Crossref
Benjamin Bruno Policicchio, Paola Sette, Cuiling Xu, George Haret-Richter, Tammy Dunsmore, Ivona Pandrea, Ruy M. Ribeiro & Cristian Apetrei. (2018) Emergence of resistance mutations in simian immunodeficiency virus (SIV)-infected rhesus macaques receiving non-suppressive antiretroviral therapy (ART). PLOS ONE 13:2, pages e0190908.
Crossref
Crossref
Alison F. Feder, Christopher Kline, Patricia Polacino, Mackenzie Cottrell, Angela D. M. Kashuba, Brandon F. Keele, Shiu-Lok Hu, Dmitri A. Petrov, Pleuni S. Pennings & Zandrea Ambrose. (2017) A spatio-temporal assessment of simian/human immunodeficiency virus (SHIV) evolution reveals a highly dynamic process within the host. PLOS Pathogens 13:5, pages e1006358.
Crossref
Crossref
Duncan Churchill, Laura Waters, Nadia Ahmed, Brian Angus, Marta Boffito, Mark Bower, David Dunn, Simon Edwards, Carol Emerson, Sarah Fidler, Martin Fisher, Rob Horne, Saye Khoo, Clifford Leen, Nicola Mackie, Neal Marshall, Fernando Monteiro, Mark Nelson, Chloe Orkin, Adrian Palfreeman, Sarah Pett, Andrew Phillips, Frank Post, Anton Pozniak, Iain Reeves, Caroline Sabin, Roy Trevelion, John Walsh, Ed Wilkins, Ian Williams & Alan Winston. (2016) British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV Medicine 17, pages s2-s104.
Crossref
Crossref
Mohammed Lamorde, Jonathan M. Schapiro, David Burger & David J. Back. (2014) Antiretroviral drugs for prevention of mother-to-child transmission. AIDS 28:17, pages 2551-2563.
Crossref
Crossref
Hugues Charest, Florence Doualla-Bell, Régis Cantin, Donald G. Murphy, Linda Lemieux, Bluma Brenner, Isabelle Hardy, Daniela Moisi, Ernest Lo, Jean-Guy Baril, Mark A. Wainberg, Michel Roger & Cécile Tremblay. (2014) A Significant Reduction in the Frequency of HIV-1 Drug Resistance in Québec from 2001 to 2011 Is Associated with a Decrease in the Monitored Viral Load. PLoS ONE 9:10, pages e109420.
Crossref
Crossref
Frederik N. Engsig, Jan Gerstoft, Marie Helleberg, Lars N. Nielsen, Gitte Kronborg, Lars R. Mathiesen & Niels Obel. (2014) Effectiveness of Antiretroviral Therapy in Individuals Who for Economic Reasons Were Switched From a Once-Daily Single-Tablet Regimen to a Triple-Tablet Regimen. JAIDS Journal of Acquired Immune Deficiency Syndromes 66:4, pages 407-413.
Crossref
Crossref
F. Raffi & J. Reynes. (2014) Antiretroviral treatment French guidelines 2013: economics influencing science. Journal of Antimicrobial Chemotherapy 69:5, pages 1158-1161.
Crossref
Crossref
Naomi Bulteel, Loveleen Bansi-Matharu, Duncan Churchill, David Dunn, David Bibby, Teresa Hill, Caroline Sabin & Mark Nelson. (2014) The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort. Journal of Infection 68:1, pages 77-84.
Crossref
Crossref
P. Frange, S. Blanche & M.-L. Chaix. (2013) Emtricitabine compared with lamivudine may preserve future therapeutic options in HIV-1-infected children. Journal of Antimicrobial Chemotherapy 68:11, pages 2694-2695.
Crossref
Crossref
Francesc Homar, Virginia Lozano, Juan Martínez-Gómez, Itziar Oyagüez, Antonio Pareja, Antoni Payeras, Joaquín Serrano, Carmen Carratalá & Miguel Ángel Casado. (2012) Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs. Health Economics Review 2:1.
Crossref
Crossref
Randall Tressler & Catherine Godfrey. (2012) NRTI Backbone in HIV Treatment. Drugs 72:16, pages 2051-2062.
Crossref
Crossref
Selwyn J. Hurwitz & Raymond F. Schinazi. (2012) Practical considerations for developing nucleoside reverse transcriptase inhibitors. Drug Discovery Today: Technologies 9:3, pages e183-e193.
Crossref
Crossref
Barbara A. Rath, Richard A. Olshen, Jerry Halpern & Thomas C. Merigan. (2012) Persistence versus Reversion of 3TC Resistance in HIV-1 Determine the Rate of Emergence of NVP Resistance. Viruses 4:8, pages 1212-1234.
Crossref
Crossref
A. G. Marcelin, C. Charpentier, M. Wirden, R. Landman, M. A. Valantin, A. Simon, C. Katlama, P. Yeni, D. Descamps, C. Aubron-Olivier & V. Calvez. (2012) Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens. Journal of Antimicrobial Chemotherapy 67:6, pages 1475-1478.
Crossref
Crossref